2-Acetamido-3-(1-methylimidazol-4-yl)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Acetamido-3-(1-methylimidazol-4-yl)propanoic acid
• 英文别名: 2-acetamido-3-(1-methylimidazol-4-yl)propanoic acid
• 化学式: C₉H₁₃N₃O₃
• 分子量: 211.22
• InChiKey: GVRCKHXHWSYDEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  84.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• METABOLICS BIOMARKER FOR NAFLD AND METHODS OF USE
  申请人：Duke University

  公开号：US20170138967A1

  公开（公告）日：2017-05-18

  The present disclosure provides metabolomics biomarkers for NAFLD and indicative of liver fibrosis and methods of using same.
• PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170276669A1

  公开（公告）日：2017-09-28

  The present invention relates to the field of nephrology. More specifically, the present invention provides methods and compositions useful for more precisely estimating glomerular filtration rate (GFR). In a specific embodiment, a method for calculating the estimated glomerular filtration rate (eGFR) in a patient comprises the steps of (a) measuring the level of one or more metabolites using mass spectrometry from a blood sample obtained from the patient; and (b) calculating the eGFR using an algorithm that utilizes the measured levels of the one or more metabolites.
• System, Method and Apparatus for Determining the Effect of Genetic Variants
  申请人：METABOLON, INC.

  公开号：US20180314790A1

  公开（公告）日：2018-11-01

  Methods using a combination of metabolomics and computer technology to determine sequence variants with potential negative or detrimental effects and enable the classification of a variant with an unknown or uncertain clinical significance from VUS status to benign, pathogenic or advantageous are described. For example, methods of using metabolomics to expedite personalized medicine based on genomic sequence analysis are described. Using metabolic profiles to determine (or aid in determining) the significance of genetic variants and enable the identification of diagnostic variants (those variants having a detrimental health affect) for use in personalized medicine is described. Further, using metabolic profiles to determine the presence of advantageous variants that may have a positive effect on patient health is also described.
• METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLOMIC MODULATORS
  申请人：The Regents of the University of California

  公开号：US20210364526A1

  公开（公告）日：2021-11-25

  Provided herein are methods for selecting a subject with a disease or disorder for treatment, as well as methods of treating the subject, determining the efficacy of the treatment, and adjusting the treatment dosage and frequency.
• [EN] PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS<br/>[FR] ESTIMATION PRÉCISE DU DÉBIT DE FILTRATION GLOMÉRULAIRE À PARTIR DE PLUSIEURS BIOMARQUEURS
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2016025429A1

  公开（公告）日：2016-02-18

  The present invention relates to the field of nephrology. More specifically, the present invention provides methods and compositions useful for more precisely estimating glomerular filtration rate (GFR). In a specific embodiment, a method for calculating the estimated glomerular filtration rate (eGFR) in a patient comprises the steps of (a) measuring the level of one or more metabolites using mass spectrometry from a blood sample obtained from the patient; and (b) calculating the eGFR using an algorithm that utilizes the measured levels of the one or more metabolites.